Comments
Loading...

Avadel Pharmaceuticals Analyst Ratings

AVDLNASDAQ
Logo brought to you by Benzinga Data
$8.12
0.000.00%
Pre-Market: 4:24 PM EDT
Consensus Rating1
Buy
Highest Price Target1
$30.00
Lowest Price Target1
$11.00
Consensus Price Target1
$17.91

Avadel Pharmaceuticals Analyst Ratings and Price Targets | NASDAQ:AVDL | Benzinga

Avadel Pharmaceuticals PLC has a consensus price target of $17.91 based on the ratings of 11 analysts. The high is $30 issued by Oppenheimer on October 31, 2024. The low is $11 issued by Jefferies on November 30, 2022. The 3 most-recent analyst ratings were released by Needham, HC Wainwright & Co., and Needham on March 4, 2025, March 4, 2025, and March 3, 2025, respectively. With an average price target of $19.67 between Needham, HC Wainwright & Co., and Needham, there's an implied 142.20% upside for Avadel Pharmaceuticals PLC from these most-recent analyst ratings.

Analyst Trends and Forecast
5
Oct 24
3
Nov 24
4
Jan
1
Feb
3
Mar
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
4.2
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

Needham
HC Wainwright & Co.
Deutsche Bank
UBS
Piper Sandler

1calculated from analyst ratings

Analyst Ratings for Avadel Pharmaceuticals

Buy NowGet Alert
03/04/2025Buy Now133.99%Needham
Ami Fadia62%
$19 → $19ReiteratesBuy → BuyGet Alert
03/04/2025Buy Now158.62%HC Wainwright & Co.
Oren Livnat61%
$21 → $21ReiteratesBuy → BuyGet Alert
03/03/2025Buy Now133.99%Needham
Ami Fadia62%
$19 → $19ReiteratesBuy → BuyGet Alert
02/11/2025Buy Now47.78%Deutsche Bank
David Hoang43%
→ $12Initiates → BuyGet Alert
01/13/2025Buy Now72.41%UBS
Ashwani Verma48%
$22 → $14MaintainsBuyGet Alert
01/10/2025Buy Now60.1%Piper Sandler
David Amsellem69%
$24 → $13MaintainsOverweightGet Alert
01/10/2025Buy Now158.62%HC Wainwright & Co.
Oren Livnat61%
$25 → $21ReiteratesBuy → BuyGet Alert
01/09/2025Buy Now133.99%Needham
Ami Fadia62%
$22 → $19MaintainsBuyGet Alert
11/13/2024Buy Now207.88%HC Wainwright & Co.
Oren Livnat61%
$27 → $25MaintainsBuyGet Alert
11/13/2024Buy Now170.94%Needham
Ami Fadia62%
$22 → $22ReiteratesBuy → BuyGet Alert
11/12/2024Buy Now170.94%Needham
Ami Fadia62%
$22 → $22ReiteratesBuy → BuyGet Alert
10/31/2024Buy Now232.51%HC Wainwright & Co.
Oren Livnat61%
$27 → $27ReiteratesBuy → BuyGet Alert
10/31/2024Buy Now269.46%Oppenheimer
Francois Brisebois44%
$29 → $30MaintainsOutperformGet Alert
10/31/2024Buy Now170.94%Needham
Ami Fadia62%
$22 → $22ReiteratesBuy → BuyGet Alert
10/21/2024Buy Now232.51%HC Wainwright & Co.
Oren Livnat61%
$27 → $27ReiteratesBuy → BuyGet Alert
10/18/2024Buy Now170.94%Needham
Ami Fadia62%
$22 → $22ReiteratesBuy → BuyGet Alert
09/04/2024Buy Now170.94%Needham
Ami Fadia62%
$22 → $22ReiteratesBuy → BuyGet Alert
08/29/2024Buy Now170.94%Needham
Ami Fadia62%
$22 → $22ReiteratesBuy → BuyGet Alert
08/28/2024Buy Now232.51%HC Wainwright & Co.
Oren Livnat61%
$27 → $27ReiteratesBuy → BuyGet Alert
08/09/2024Buy Now170.94%Needham
Ami Fadia62%
$22 → $22ReiteratesBuy → BuyGet Alert
05/09/2024Buy Now170.94%Needham
Ami Fadia62%
$22 → $22ReiteratesBuy → BuyGet Alert
05/09/2024Buy Now232.51%HC Wainwright & Co.
Oren Livnat61%
$25 → $27MaintainsBuyGet Alert
05/09/2024Buy Now183.25%Craig-Hallum
Chase Knickerbocker50%
$22 → $23MaintainsBuyGet Alert
05/08/2024Buy Now170.94%Needham
Ami Fadia62%
$22 → $22ReiteratesBuy → BuyGet Alert
04/09/2024Buy Now170.94%Needham
Ami Fadia62%
$22 → $22ReiteratesBuy → BuyGet Alert
03/05/2024Buy Now170.94%Craig-Hallum
Chase Knickerbocker50%
$20 → $22MaintainsBuyGet Alert
03/05/2024Buy Now183.25%Piper Sandler
David Amsellem69%
$18 → $23MaintainsOverweightGet Alert
03/05/2024Buy Now257.14%Oppenheimer
Francois Brisebois44%
$27 → $29MaintainsOutperformGet Alert
03/05/2024Buy Now207.88%HC Wainwright & Co.
Oren Livnat61%
$21 → $25MaintainsBuyGet Alert
03/05/2024Buy Now170.94%Needham
Ami Fadia62%
$20 → $22MaintainsBuyGet Alert
02/06/2024Buy Now158.62%UBS
Ashwani Verma48%
→ $21Initiates → BuyGet Alert
12/20/2023Buy Now146.31%Needham
Ami Fadia62%
$19 → $20MaintainsBuyGet Alert
11/09/2023Buy Now133.99%Needham
Ami Fadia62%
$18 → $19MaintainsBuyGet Alert
10/04/2023Buy Now121.67%Needham
Ami Fadia62%
→ $18ReiteratesBuy → BuyGet Alert
09/25/2023Buy Now121.67%Needham
Ami Fadia62%
→ $18ReiteratesBuy → BuyGet Alert
08/10/2023Buy Now121.67%Piper Sandler
David Amsellem69%
$13 → $18MaintainsOverweightGet Alert
08/10/2023Buy Now121.67%Needham
Ami Fadia62%
→ $18ReiteratesBuy → BuyGet Alert
08/10/2023Buy Now158.62%HC Wainwright & Co.
Oren Livnat61%
→ $21ReiteratesBuy → BuyGet Alert
08/09/2023Buy Now121.67%Needham
Ami Fadia62%
→ $18Reiterates → BuyGet Alert
07/05/2023Buy Now158.62%HC Wainwright & Co.
Oren Livnat61%
$17.5 → $21ReiteratesBuy → BuyGet Alert
06/30/2023Buy Now207.88%Oppenheimer
Francois Brisebois44%
$22 → $25MaintainsMarket OutperformGet Alert
06/30/2023Buy Now121.67%Needham
Ami Fadia62%
→ $18ReiteratesBuy → BuyGet Alert
06/12/2023Buy Now170.94%Oppenheimer
Francois Brisebois44%
→ $22ReiteratesOutperform → OutperformGet Alert
05/30/2023Buy Now121.67%Needham
Ami Fadia62%
$14 → $18Reiterates → BuyGet Alert
05/02/2023Buy Now220.2%LifeSci Capital
Patrick Dolezal69%
$17 → $26MaintainsOutperformGet Alert
05/02/2023Buy Now97.04%Ladenburg Thalmann
Matthew Kaplan66%
$14.5 → $16MaintainsBuyGet Alert
05/02/2023Buy Now170.94%Oppenheimer
Francois Brisebois44%
$20 → $22MaintainsOutperformGet Alert
05/02/2023Buy Now115.52%HC Wainwright & Co.
Oren Livnat61%
$14 → $17.5MaintainsBuyGet Alert
05/02/2023Buy Now72.41%Needham
Ami Fadia62%
$12 → $14MaintainsBuyGet Alert
04/28/2023Buy Now47.78%Needham
Ami Fadia62%
→ $12Reiterates → BuyGet Alert
04/17/2023Buy Now35.47%Needham
Ami Fadia62%
→ $11MaintainsBuyGet Alert
04/03/2023Buy Now146.31%Oppenheimer
Francois Brisebois44%
→ $20Reiterates → OutperformGet Alert
04/03/2023Buy Now35.47%Needham
Ami Fadia62%
→ $11Reiterates → BuyGet Alert
03/23/2023Buy Now72.41%HC Wainwright & Co.
Oren Livnat61%
$13 → $14MaintainsBuyGet Alert
02/27/2023Buy Now146.31%Oppenheimer
Francois Brisebois44%
$19 → $20MaintainsOutperformGet Alert
02/24/2023Buy Now35.47%Needham
Ami Fadia62%
→ $11MaintainsBuyGet Alert
02/07/2023Buy Now60.1%HC Wainwright & Co.
Oren Livnat61%
→ $13Reiterates → BuyGet Alert
02/07/2023Buy Now35.47%Needham
Ami Fadia62%
→ $11Reiterates → BuyGet Alert
11/30/2022Buy Now35.47%Jefferies
Chris Howerton63%
$6.5 → $11UpgradeHold → BuyGet Alert
11/21/2022Buy Now10.84%Needham
Ami Fadia62%
$8 → $9MaintainsBuyGet Alert
08/11/2022Buy Now47.78%SVB Leerink
Marc Goodman73%
$6 → $12MaintainsOutperformGet Alert
08/10/2022Buy Now10.84%Needham
Ami Fadia62%
$6 → $9MaintainsBuyGet Alert
08/10/2022Buy Now-1.48%Jefferies
Chris Howerton63%
$6 → $8DowngradeBuy → HoldGet Alert
05/31/2022Buy Now-26.11%Needham
Ami Fadia62%
$14 → $6MaintainsBuyGet Alert
05/27/2022Buy Now60.1%HC Wainwright & Co.
Oren Livnat61%
$17 → $13MaintainsBuyGet Alert
05/27/2022Buy Now-26.11%SVB Leerink
Marc Goodman73%
$18 → $6MaintainsOutperformGet Alert

FAQ

Q

What is the target price for Avadel Pharmaceuticals (AVDL) stock?

A

The latest price target for Avadel Pharmaceuticals (NASDAQ:AVDL) was reported by Needham on March 4, 2025. The analyst firm set a price target for $19.00 expecting AVDL to rise to within 12 months (a possible 133.99% upside). 25 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Avadel Pharmaceuticals (AVDL)?

A

The latest analyst rating for Avadel Pharmaceuticals (NASDAQ:AVDL) was provided by Needham, and Avadel Pharmaceuticals reiterated their buy rating.

Q

When was the last upgrade for Avadel Pharmaceuticals (AVDL)?

A

The last upgrade for Avadel Pharmaceuticals PLC happened on November 30, 2022 when Jefferies raised their price target to $11. Jefferies previously had a hold for Avadel Pharmaceuticals PLC.

Q

When was the last downgrade for Avadel Pharmaceuticals (AVDL)?

A

The last downgrade for Avadel Pharmaceuticals PLC happened on August 10, 2022 when Jefferies changed their price target from $6 to $8 for Avadel Pharmaceuticals PLC.

Q

When is the next analyst rating going to be posted or updated for Avadel Pharmaceuticals (AVDL)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Avadel Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Avadel Pharmaceuticals was filed on March 4, 2025 so you should expect the next rating to be made available sometime around March 4, 2026.

Q

Is the Analyst Rating Avadel Pharmaceuticals (AVDL) correct?

A

While ratings are subjective and will change, the latest Avadel Pharmaceuticals (AVDL) rating was a reiterated with a price target of $19.00 to $19.00. The current price Avadel Pharmaceuticals (AVDL) is trading at is $8.12, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.